Evidence from both papillary thyroid carcinoma and triple-negative breast cancer suggests that elevated CXCL10 expression consistently correlates with improved prognosis, likely reflecting its role in promoting antitumor immune responses across distinct tumor types (42, 43). This evidence concerns the gene CXCL10 and differentiated thyroid carcinoma.